Navigation Links
Joslin researchers increase understanding of genetic risk factor for type 1 diabetes
Date:11/28/2012

BOSTON November 28, 2012 As part of their ongoing research on the role of genes in the development of type 1 diabetes, Joslin Diabetes Center scientists, in collaboration with scientists at the University of Wrzburg, have demonstrated how a genetic variant associated with type 1 diabetes and other autoimmune diseases influences susceptibility to autoimmunity. The findings appear in the upcoming issue of Diabetes.

Recent studies of the human genome have identified genetic regions associated with autoimmune diseases such as type 1 diabetes. Joslin scientists in the Section of Immunobiology seek to understand how genes that are most widely associated with various autoimmune diseases contribute to disease risk.

One of these genes is PTPN22, which plays a role in lymphocyte (immune cell) function. A PTPN22 variant (or mutation) has been implicated as a risk factor for type 1 diabetes and several other autoimmune disorders. PTPN22 is involved in the formation of a key protein known as lymphoid tyrosine phosphatase (LYP), which helps control the activity of T and B cells in the immune system. The PTPN22 mutation generates a variation of LYP with a different molecular structure.

Most studies of the PTPN22 disease variant have suggested that this variant is a gain-of-function genetic mutation that enhances LYP activity and lessens the activity of T and B cells, which increases susceptibility to autoimmunity. "When immune cells are less reactive during the maturation phase of their development, the cells can evade mechanisms that help protect against autoimmunity," says study lead author Stephan Kissler, PhD, of the Section of Immunobiology. However, one study which analyzed data from humans and genetically modified mice suggested that the LYP variant associated with type 1 diabetes is a loss-of-function mutation that reduces LYP activity.

To help resolve the conflicting data, Joslin scientists conducted studies with a unique mouse model developed by Dr. Kissler's graduate student and co-author, Peilin Zheng. Using a technology that combines RNA interference, a method to silence gene expresson, with lentiviral transgenesis, a method to genetically modify animals, the scientists can manipulate gene activity in the most widely used mouse model for type 1 diabetes, the nonobese diabetic mouse (NOD). In this study, the researchers were able to easily turn off and on the PTPN22 gene in the NOD mouse. "We are the first to use this approach in the NOD mouse model," says Dr. Kissler. "It provides a very powerful way to study the contribution of PTPN22 to disease."

When PTPN22 was turned off in mice, mimicking a loss-of-function mutation, the researchers observed an increase in regulatory T cells and a decreased risk of autoimmune diabetes. "This is the first study conducted on the diabetic mouse model that supports the LYP gain-of-function hypothesis," says Dr. Kissler. "Our work should help to resolve the controversy."

By providing additional data that suggests the potential therapeutic value of PTPN22 manipulation, the study may further the development of new therapeutic options that inhibit LYP to reduce or prevent autoimmunity. "Our goal is to treat autoimmunity. Inhibiting LYP in patients may increase regulatory immune cells and could confer protection against autoimmunity, but it remains to be tested if our promising findings in this mouse model are reflected in humans," says Dr. Kissler.

The Joslin scientists are following up on this study to deepen understanding of how inhibiting PTPN22 affects T and B cells.


'/>"/>

Contact: Jeffrey Bright
jeffrey.bright@joslin.harvard.edu
617-309-1957
Joslin Diabetes Center
Source:Eurekalert  

Related biology news :

1. Joslin researchers gain new understanding of diabetes and kidney disease
2. Fracking in Michigan: U-M researchers study potential impact on health, environment, economy
3. NREL researchers use imaging technologies to solve puzzle of plant architecture
4. NIH-funded researchers show possible trigger for MS nerve damage
5. Temple-Penn researchers identify calcium accelerator to keep cell power supply going
6. Researchers detail the migrations of the wood wasp Sirex noctilio
7. Researchers identify a simple way to precipitate phosphorus from the wastewater of a pulp mill
8. Researchers decode birch tree genome sequence for the first time
9. Researchers develop guidebook for promoting healthy lifestyles among Hispanic populations
10. Researchers study links between conflict and fisheries in East Africa
11. A class of RNA molecules protects germ cells from damage, Penn vet researchers show
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Joslin researchers increase understanding of genetic risk factor for type 1 diabetes
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/14/2017)...  Wake Forest Baptist Medical Center today announced Julie Ann ... officer (CEO). Freischlag joins the medical center on May ... M.D., who last year announced that he would transition ... leading it since 2008.   As CEO, ... Baptist,s academic health system, which includes Wake Forest School ...
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
Breaking Biology News(10 mins):
(Date:2/21/2017)... Feb. 21, 2017 Synthetic Biologics, Inc. (NYSE ... the microbiome to protect and restore the health of patients, intends ... December 31, 2016 on Thursday, March 2, 2017, and to host ... dial-in information for the call is as follows: U.S. ... ...
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... ... to announce that Dr. Trevor Heritage has joined its executive team to lead ... system designed to provide insights to help improve the diagnosis and treatment of ...
(Date:2/21/2017)... VANCOUVER, British Columbia , Feb. 21, 2017 ... announced that apatorsen results from two randomized Phase 2 clinical ... (ASCO) 2017 Genitourinary Cancers Symposium, held February 16 th - ... data from trials in bladder and prostate cancers demonstrated apatorsen ... with standard-of-care treatments. ...
(Date:2/21/2017)... Feb 21, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 12.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology Technology: